Evidence map›Paper›PMID 32326970›Full record

ArticleJournal of experimental & clinical cancer research : CR2020

A novel ETV6-miR-429-CRKL regulatory circuitry contributes to aggressiveness of hepatocellular carcinoma.

Chunmei Guo, Chao Gao, Dongting Zhao, Jiahui Li, Jinxia Wang, Xujuan Sun, Qinlong Liu, Lihong Hao, Frederick T Greenaway, Yuxiang Tian and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Expression and prognostic significance of CRKL in clear cell renal cell carcinoma.American journal of clinical and experimental immunology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Chunmei Guo *Department of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Chao Gao *Department of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Dongting Zhao *Department of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Jiahui LiDepartment of Biochemistry, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Jinxia WangDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Xujuan SunDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Qinlong LiuDepartment of General Surgery, The Second Affiliated Hospital, Dalian Medical University, Dalian, 116044, China.
Lihong HaoDepartment of Histology and Embryology, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Frederick T GreenawayCarlson School of Chemistry and Biochemistry, Clark University, Worcester, MA, 01610, USA.
Yuxiang TianDepartment of Biochemistry, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Shuqing LiuDepartment of Biochemistry, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China. lsqsmz@163.com.
Ming-Zhong SunDepartment of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China. smzlsq@163.com.
Dalian Medical University · CNClark University · US

Funding

National Natural Science Foundation of China 31900517National Natural Science Foundation of China 81272186National Natural Science Foundation of China 81672737Natural Science Foundation of Liaoning Province 20181550168Natural Science Foundation of Liaoning Province LQ2017001Natural Science Foundation of Liaoning Province LZ2019003
6 · The paper itself

Abstract

backgroundTumor metastasis is one of the main causes of the high mortality of hepatocellular carcinoma (HCC). E-Twenty Six variant gene 6 (ETV6) is a strong transcriptional repressor, associated with the development and progression of tumors. However, the exact role and underlying mechanism of ETV6 in HCC remain unclear.

methodsWestern blotting, quantitative real-time PCR and immunohistochemistry were used to detect the expression levels of ETV6, CRKL (v-crk sarcoma virus CT10 oncogene homologue (avian)-like) and miR-429 in HCC tissues and cells; Transwell chamber and F-actin cytoskeleton staining assay to examine the effects of ETV6 and CRKL deregulation on the migration, invasion and cytoskeleton of HCC cells; Co-immunoprecipitation assay to determine the interaction between CRKL and ETV6; Chromatin immunoprecipitation assay to investigate the interaction between ETV6 and miR-429.

resultsWe established a novel ETV6-miR-429-CRKL regulatory circuitry contributes to HCC metastasis. ETV6 and CRKL were frequently increased, while miR-429 was downregulated in both hepatocarcinoma tissues and hepatocarcinoma cells. Moreover, ETV6 upregulation was positively correlated with CRKL upregulation, and two negative correlations were also established for ETV6 and CRKL upregulation with miR-429 downregulation in both hepatocarcinoma patients' tumorous tissues and hepatocarcinoma cells. Functional investigations revealed that overexpression and knockdown of ETV6 was remarkably effective in promoting and suppressing HCC cell migration, invasion, cytoskeleton F-actin expression and arrangement, whereas, CRKL overexpression exhibited similar effects to the overexpression of ETV6. Mechanistically, ETV6 negatively regulates miR-429 expression by directly binding to the promoter region of miR-429; miR-429 negatively regulates CRKL expression by selectively targeting CRKL-3'-UTR; ETV6 directly binds to CRKL and positively regulates its expression, which in turn CRKL positively regulates ETV6 expression.

conclusionsOur data demonstrated that ETV6 promotes migration and invasion of HCC cells by directly binding to promoter region of miR-429 via modulating CRKL expression. The newly identified ETV6-miR-429-CRKL regulatory circuitry contributes to the aggressiveness of HCC, which provides new clues for fundamental research on diagnosis and treatment parameters for HCC.

Indexed as

Adaptor Proteins, Signal TransducingCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationETS Translocation Variant 6 ProteinFemaleGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMaleMicroRNAsMiddle AgedProto-Oncogene Proteins c-etsRepressor ProteinsAdaptor Proteins, Signal TransducingCRKL proteinETS Translocation Variant 6 ProteinMicroRNAsMIRN429 microRNA, humanProto-Oncogene Proteins c-etsRepressor ProteinsETV6-miR-429-CRKL regulatory circuitryHepatocellular carcinomaMalignancy

Identifiers

PMID32326970
PMCPMC7178969
OpenAlexW3018149397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.